Should oral bisphosphonates be standard of care in women with early breast cancer?

被引：4

作者：

Clemons, M ^{[1
]}

Verma, S ^{[1
]}

机构：

[1] Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 90卷 / 03期

关键词：

adjuvant therapy; bisphosphonates; bone mets; breast cancer;

D O I：

10.1007/s10549-004-4259-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is increasing evidence that oral clodronate has important clinical benefits in early breast cancer. Longer-term follow-up data from two out of three randomized studies have shown that adjuvant clodronate improves survival. This article outlines the results of these studies and discusses the potential role for other bisphosphonates, such as ibandronate and zoledronic acid, in the adjuvant treatment of breast cancer.

引用

页码：315 / 318

页数：4

共 28 条

[1] Renal safety of ibandronate in patients with bone metastases from breast cancer:: phase III trial results [J].

Bell, R. ;

Diel, I. J. ;

Body, J. ;

Bergstroem, B. .

EJC SUPPLEMENTS, 2004, 2 (03) :132-132

[2] Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].

Body, JJ ;

Diel, IJ ;

Lichinitzer, M ;

Lazarev, A ;

Pecherstorfer, M ;

Bell, R ;

Tripathy, D ;

Bergstronn, B .

BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137

[3]

Boissier S, 2000, CANCER RES, V60, P2949

[4]

Borner M, 2001, ONCOLOGIST, V6, P12

[5]

Coleman R, 2004, BONE, V34, pS85

[6]

Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO

[7]

2-Z

[8]

DIEL IJ, 2000, P AN M AM SOC CLIN, V19, P314

[9]

Fournier P, 2002, CANCER RES, V62, P6538

[10] Bisphosphonates induce breast cancer cell death in vitro [J].

Fromigue, O ;

Lagneaux, L ;

Body, JJ .

JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (11) :2211-2221

← 1 2 3 →